Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05772520 · ClinicalTrials.gov registry record · Phase 2
The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis
A Phase 2 study of Plaque Psoriasis, sponsored by Hangzhou Highlightll Pharmaceutical Co..
- Completed
- Registry status
- Phase 2
- Development phase
- 82
- Enrollment target
- 20
- Study locations
NCT05772520: Completed Phase 2 study of Plaque Psoriasis, sponsored by Hangzhou Highlightll Pharmaceutical Co..
NCT05772520 is a Phase 2 study of Plaque Psoriasis that has completed, run by Hangzhou Highlightll Pharmaceutical Co.. The registered enrollment target is 82 participants, below the 414-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05772520, a Phase 2 study of Plaque Psoriasis, has completed, sponsored by Hangzhou Highlightll Pharmaceutical Co..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 82 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2, multicenter, randomized, double-blinded, parallel dose group, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of 2 doses of TLL018 as therapy in approximately 90 participants with moderate-to-severe PP.
Primary Outcome
A PASI 75 response is defined as achieving at least a 75% improvement (reduction) in the Psoriasis Area and Severity Index (PASI) score from baseline. The PASI is a composite tool that assesses the overall severity of erythema, induration, and scaling, as well as the extent of body surface area involvement. The total PASI score ranges from 0 to 72, with higher scores indicating more severe disease. The results are in Full Analysis Set (FAS).
Conditions Studied
Interventions
- DRUG TLL018 tablets
Study Locations (20)
Florida
- Life Clinical Trials - Coral Springs
- Palm Beach - DeLand
- D&H Doral Research Center LLC - Doral
- Sweet Hope Research Specialty, Inc - Hialeah
- CNS - Jacksonville - Jacksonville
- CNS - Orlando SODO - Jacksonville
- Altus Research - Lake Worth
- Anchor Medical Research, LLC (Core Clinical Trials) - Miami
- Reserka Research - Miami
- ForCare Medical (CenExcel) - Tampa
California
- Moy, Fincher, Chipps - Beverly Hills
- Metropolis Derm - Los Angeles
- Amicis Research Center - Northridge
- Integrative Skin - Sacramento
- Skin Surgical - San Diego
Alabama
- Cahaba - Birmingham
Iowa
- Integrated Clinical Trial Services, Inc - Des Moines
Louisiana
- IMA Clinical Research - Monroe
Maryland
- Lawrence Green - Rockville
Massachusetts
- Metro Boston - Brighton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2023-01-19 |
| Est. Completion | 2024-12-23 |
| Phase | Phase 2 |
What the finished NCT05772520 record still lists
NCT05772520 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 82 participants, a relatively small participant target, below the 414-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which TLL018 tablets is the first listed.
NCT05772520 names 20 study sites across 7 states, led by Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT05772520 about?
NCT05772520 is a clinical study titled "The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis". This is a Phase 2, multicenter, randomized, double-blinded, parallel dose group, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of 2 doses of TLL018 as therapy in approximately 90 participants with moderate-to-severe PP.
What is the current status of trial NCT05772520?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 82 participants. The study started on 2023-01-19. Estimated completion is 2024-12-23.
What conditions does trial NCT05772520 study?
This clinical trial studies the following conditions: Plaque Psoriasis.
What interventions are being tested in trial NCT05772520?
The interventions under investigation include: TLL018 tablets (DRUG).
Who is sponsoring clinical trial NCT05772520?
This trial is sponsored by Hangzhou Highlightll Pharmaceutical Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05772520 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Iowa, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05772520's enrollment target sits among peer trials
82 32nd of 45 higher than 14 of 45 other Plaque Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Plaque Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
RECRUITING · Phase 2
-
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
RECRUITING · Phase 2
-
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 2
-
ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 2
-
Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 2
-
Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03319901 · 82 participants · Phase 1
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
- NCT03493425 · 82 participants · Phase 2
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
- NCT04105270 · 82 participants · Phase 2
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
- NCT04428658 · 82 participants · NA
Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI